Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MLYCD | O95822 | 12/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10072178 | 0.74 | MLYCD (0.48) | MLYCD | |
| SCHEMBL14214318 | 0.73 | MAOB (0.50) | MEN1MAPK10KMT2AMAOBAPAF1 | |
| SCHEMBL8578279 | 0.71 | MAOB (0.51) | MEN1MAPK10KMT2AMAOBAPAF1 | |
| SCHEMBL8578277 | 0.69 | MAOB (0.50) | MEN1MAPK10KMT2AMAOBAPAF1 | |
| SCHEMBL14183685 | 0.69 | NPC1 (0.52) | MAOB | |
| SCHEMBL20117267 | 0.69 | MIF (0.39) | MAOB | |
| SCHEMBL8243017 | 0.68 | MIF (0.52) | MAOB | |
| SCHEMBL3983301 | 0.68 | MEN1 (0.60) | MEN1MAPK10KMT2AAPAF1POLB | |
| SCHEMBL649021 | 0.67 | MLYCD (0.45) | MLYCD | |
| SCHEMBL12868401 | 0.67 | MLYCD (0.51) | MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119819-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-02-21 | — | — | US | disclosed |
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | disclosed |
| EP-1411929-B1 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2011-05-11 | — | — | EP | disclosed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524969-B2 | Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1411929-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003090869-A1 | LXR MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002058698-A2 | MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016259-A1 | Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators | MLYCD, ME3, ACACA | MEN1 1149/4885MAPK10 1828/4885KMT2A 1243/4885 |
| US-20040082576-A1 | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | MLYCD, ME3, ACACA | MEN1 1149/4885MAPK10 1828/4885KMT2A 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.